Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NEO 
NeoGenomics Inc (NEO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: NEO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.44
1 Year Target Price $13.44
| 6 | Strong Buy |
| 2 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.35% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.57B USD | Price to earnings Ratio - | 1Y Target Price 13.44 |
Price to earnings Ratio - | 1Y Target Price 13.44 | ||
Volume (30-day avg) 14 | Beta 1.62 | 52 Weeks Range 4.72 - 19.11 | Updated Date 12/4/2025 |
52 Weeks Range 4.72 - 19.11 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -16% | Operating Margin (TTM) -8.09% |
Management Effectiveness
Return on Assets (TTM) -3.03% | Return on Equity (TTM) -12.99% |
Valuation
Trailing PE - | Forward PE 222.22 | Enterprise Value 1814371148 | Price to Sales(TTM) 2.22 |
Enterprise Value 1814371148 | Price to Sales(TTM) 2.22 | ||
Enterprise Value to Revenue 2.56 | Enterprise Value to EBITDA -27.92 | Shares Outstanding 129387801 | Shares Floating 119428822 |
Shares Outstanding 129387801 | Shares Floating 119428822 | ||
Percent Insiders 1.28 | Percent Institutions 102.08 |
Upturn AI SWOT
NeoGenomics Inc
Company Overview
History and Background
NeoGenomics Inc. was founded in 2001. It has grown through acquisitions and organic expansion to become a leading cancer testing and information services company. Initially focused on cytogenetics, it expanded into molecular testing and other areas of oncology diagnostics.
Core Business Areas
- Pharma Services: Provides testing services to pharmaceutical companies to support drug development, clinical trials, and companion diagnostics.
- Clinical Services: Offers a wide range of genetic and molecular tests to hospitals, oncology practices, and other healthcare providers to aid in cancer diagnosis, prognosis, and treatment decisions.
Leadership and Structure
The leadership team is headed by the CEO. The company has a functional organizational structure with departments such as research and development, operations, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- Comprehensive Genomic Profiling (CGP): NeoGenomics offers CGP tests that analyze a large number of genes to identify mutations and other genomic alterations in cancer cells. This aids in identifying targeted therapies and clinical trial options. Competitors include Foundation Medicine (owned by Roche), Caris Life Sciences, and Guardant Health. Revenue from CGP accounts for a significant portion of clinical service revenue.
- Flow Cytometry: NeoGenomics provides flow cytometry services for the diagnosis and monitoring of hematologic malignancies. Competitors include Labcorp and Quest Diagnostics.
- Fluorescence in situ Hybridization (FISH): NeoGenomics offers FISH testing for various cancers. Competitors include Labcorp and Quest Diagnostics.
- IHC (immunohistochemistry): IHC (immunohistochemistry) testing services for various cancers. Competitors include Labcorp and Quest Diagnostics.
Market Dynamics
Industry Overview
The oncology diagnostics market is growing due to the increasing prevalence of cancer, advancements in genomic technologies, and the rise of personalized medicine. The market is competitive, with a mix of large diagnostic companies and specialized players.
Positioning
NeoGenomics is a major player in the oncology diagnostics market, particularly in the clinical testing segment and pharma services. Its competitive advantages include a broad test menu, a strong focus on oncology, and established relationships with healthcare providers and pharmaceutical companies.
Total Addressable Market (TAM)
The total addressable market is estimated to be in the tens of billions of dollars. NeoGenomics is positioned to capture a significant share of this market through its comprehensive testing services and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Comprehensive test menu
- Strong focus on oncology
- Established relationships with healthcare providers and pharma companies
- Expertise in genomic testing
- Strong brand recognition
Weaknesses
- Reliance on third-party reimbursement
- Exposure to regulatory changes
- Price competition
- Integration risks from acquisitions
- Past history of reporting inaccuracies
Opportunities
- Expanding into new markets
- Developing new tests and services
- Partnering with pharmaceutical companies
- Increasing adoption of personalized medicine
- Growth in liquid biopsy testing
Threats
- Competition from larger diagnostic companies
- Changes in reimbursement policies
- Technological advancements that could disrupt the market
- Economic downturn
- Data privacy and security concerns
Competitors and Market Share
Key Competitors
- Roche Holding Ltd (RHHBY)
- Laboratory Corporation of America Holdings (LH)
- Quest Diagnostics Incorporated (DGX)
- Caris Life Sciences
- Guardant Health (GH)
Competitive Landscape
NeoGenomics faces competition from larger, more established diagnostic companies and specialized players. Its advantages include a focus on oncology and a broad test menu. However, it needs to improve its financial performance and maintain its competitive edge in genomic testing.
Major Acquisitions
Inivata
- Year: 2021
- Acquisition Price (USD millions): 390
- Strategic Rationale: Acquisition of Inivata enhances NeoGenomics' liquid biopsy capabilities.
Growth Trajectory and Initiatives
Historical Growth: Historically, NeoGenomics experienced strong growth through acquisitions and increased demand for its testing services. However, recent growth has been more subdued.
Future Projections: Analyst estimates project moderate revenue growth for NeoGenomics in the coming years, driven by expanding test offerings and market penetration. Achieving profitability is a key goal.
Recent Initiatives: Recent initiatives include focusing on core oncology testing services, improving operational efficiency, and strengthening relationships with pharmaceutical partners.
Summary
NeoGenomics is a major player in the oncology diagnostics market, offering a comprehensive range of testing services. However, the company faces profitability challenges and intense competition. Its strengths lie in its focus on oncology and broad test menu, but it needs to improve its financial performance and navigate regulatory changes. Recent initiatives are focused on improving operational efficiency and strengthening partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NeoGenomics Inc
Exchange NASDAQ | Headquaters Fort Myers, FL, United States | ||
IPO Launch date 1999-11-02 | CEO & Director Mr. Anthony P. Zook | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 2200 | Website https://www.neogenomics.com |
Full time employees 2200 | Website https://www.neogenomics.com | ||
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.